Early initiation of ET-A receptor antagonism improves cardiovascular hemodynamics in severe but not mild experimental CHF

Schirger, JA; Hh, Chen; Lisý, Ondřej; Jougasaki, Michihisa; Osborn, Jenit; Kirchengast, Michael; Burnett, J. C.

doi:10.1016/s1071-9164(98)90177-4

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Systemic blood pressure remained unchanged. The authors conclude that ET-1 mediates renal and cardiovascular hemodynamic effects in severe CHF via the ET A receptor (51). The study supports a therapeutic potential for ET A receptor antagonism with LU 135252 by reversing systemic and renal vasoconstriction especially in severe heart failure.…”

Section: Congestive Heart Failure (Chf)mentioning

confidence: 53%

“…In a second study the effect of LU 135252 on cardiovascular and renal hemodynamics at two different time points was studied in a model of pacing-induced heart failure (51). Dogs were assigned randomly to four groups, and a possible dependence of the effect of ET A receptor blockade from the severity of CHF was investigated.…”

Section: Congestive Heart Failure (Chf)mentioning

confidence: 99%

See 1 more Smart Citation

Endothelin-1 and Endothelin Receptor Antagonists in Cardiovascular Remodeling

Kirchengast¹,

Munter²

1999

Experimental Biology and Medicine

View full text Add to dashboard Cite

Endothelins build a peptide family composed of three isoforms, each of them containing 21 amino acids. Endothelin-1 is the isoform mainly responsible for any cardiovascular action and therefore the sole scope of this review. Endothelin-1 is the most potent endogenous vasoconstrictor known; in addition it acts as a potent (co)mitogen. There is a substantial body of experimental evidence that endothelin-1 may contribute not only to sustained vasoconstriction, but also to remodeling within the cardiovascular system. Thus, with the help of endothelin receptor antagonists (available for a few years) the involvement of mainly ET A receptors in structural diseases such as heart failure, pulmonary hypertension, atherosclerosis, restenosis, systemic hypertension, and chronic renal failure has been shown. These data make endothelin receptor antagonists, and especially those selective for the ET A receptor, promising agents for the treatment of chronic cardiovascular diseases associated with remodeling. Currently several chemically distinct, orally available members of this novel class of therapeutic agents are under clinical investigation.

show abstract

Section: Congestive Heart Failure (Chf)mentioning

confidence: 53%

Section: Congestive Heart Failure (Chf)mentioning

confidence: 99%